包装 | 库存 | 价格 | |
---|---|---|---|
暂无数据 |
推荐产品
基本信息
英文别名WHI-P131; Jak3 inhibitor I | |
中文别名WHI-P131; Jak3 inhibitor I |
安全信息
存储条件Freezer -20℃ | Symbol |
Hazard StatementsH302 H410 | |
Precautionary StatementsP264 P270 P330 P501 P273 P391 P301+P317 | |
UN3077 | Hazard Class9 |
Packing GroupIII |
化学和物理性质
产品描述
产品描述
JANEX-1是JAK3小分子抑制剂,选择性抑制JAK3,IC50为78 μM。它不影响JAK1或JAK2,及其他蛋白酪氨酸激酶的活性(IC50 ≥ 350 µM)。
靶点(IC50 & Targe)
JAK3,Ki:2.3μM
体外研究
JANEX-1 inhibits JAK3 but not JAK1 or JAK2. The ZAP/SYK family tyrosine kinase SYK, TEC family tyrosine kinase Bruton’s tyrosine kinase (BTK), SRC family tyrosine kinase LYN, and receptor family tyrosine kinase insulin receptor kinase (IRK) are not inhibited by JANEX-1[1]. JANEX-1 suppresses IL-1β and IFN-γ-induced phosphorylation of STAT-1, STAT-3, and STAT-5 proteins. JANEX-1 has a potent inhibitory effect on cytokine-induced β-cell damage[2].
体内研究
JANEX-1 is very well tolerated by mice and monkeys and effective plasma concentrations of JANEX-1 could be achieved at nontoxic dose levels. JANEX-1 suppresses the mitogen and antigen responses of T-cells and attenuates the severity of T-cell-dependent graft-versus-host disease in a bone marrow transplantation model[1].
动物实验
Animal Models: Female NOD mice
Formulation: DMSO in PBS
Dosages: 20, 50 and 100 mg/kg/day
Administration: IP
(Only for Reference)
参考文献
[1] Cetkovic-Cvrlje M, et al. Clin Immunol. 2003, 106(3):213-25.
[2] Lv N, et al. Exp Cell Res. 2009, 315(12):2064-71.